Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Asubio Pharma

Division of Daiichi Sankyo Co. Ltd.
www.daiichipharm.co.jp

Latest From Daiichi Asubio Pharma

Deal Watch: Genzyme Validates Alnylam's Strategy By Partnering On Hemophilia Candidate

Astellas/Chromocell pain therapy collaboration centers on New Jersey biotech's platform technology, which may solve the problem of reproducing Nav1.7 receptors for in vitro assays. Xoma signs preclinical immuno-oncology partnership with Novartis, dimming the focus on Phase III flop for gevokizumab.

BioPharmaceutical Deals

Licensing PARP Inhibitor A Win For BioMarin, Medivation

BioMarin’s licensing of the PARP inhibitor talazoparib to Medivation in August reduces BioMarin’s development expenses and helps it to meet its stated goal of being non-GAAP earnings positive in 2017. Medivation gets another compound it can develop in key oncology indications it is already pursuing with its core product, the prostate cancer drug Xtandi.

BioPharmaceutical Deals

FDA Resistant to Replidyne Approval

The Food & Drug Administration's decision to require superiority studies for bronchitis and sinusitis antibiotic indications not only delayed the launch of faropenem by at least three years, it also cost Replidyne its commercial partner.
BioPharmaceutical Clinical Trials

Getting the Bugs Out of Antibiotic R&D: Commercial Implications of a Higher Regulatory Hurdle

It's a gloomy time for antibiotic R&D: higher regulatory hurdles and commercial challenges have forced many companies to leave the market. But a few major players and boutique firms remain committed to the field. What do they see that the rest of the industry is overlooking?
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Daiichi Suntory Pharma Co. Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Daiichi Sankyo Co. Ltd.
  • Senior Management
  • George Nakayama, Pres.
  • Contact Info
  • Daiichi Asubio Pharma
    Phone: (81)
    5-7-2, Kojimachi
    Tokyo,
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register